Development of an Experimental Intracranial PDX Model of Human Glioblastoma in NSG Mice
Objective: Establishment of an orthotopic intracranial model from human glioblastoma cell culture in immunodeficient mice is important both for studying the invasiveness and aggressiveness of tumor cells and for developing a reliable model for assessing the effectiveness of new drugs for glioblastoma therapy. The aim of this work was to perform a comparative study of tumorigenicity of established and primary patient-derived glioblastoma cells during subcutaneous and orthotopic intracranial xenotransplantation into immunodeficient NSG mice. Methods: The glioblastoma cell line U87MG and primary patient-derived glioblastoma cells (022 culture) were characterized in terms of morphology and molecular subtype. The expression of specific markers was analyzed by RNA-seq. Cells were xenografted into immunodeficient NSG mice either subcutaneously or orthotopically into the corpus striatum. Tumors were examined using immunohistochemical staining for glial markers. Results and Discussion: It was shown that in both groups of animals with orthotopic xenografts, tumors grew both deep into the brain tissue and on the brain surface, and in the case of the primary 022 culture, growth toward the ventricles was also noted. Morphologically, primary 022 cells had an epithelioid morphology, while U87MG cells were more sarcomatoid. Importantly, the U87MG cell line was tumorigenic in both localizations. However, the primary 022 culture formed tumors only during intracranial, but not during subcutaneous xenotransplantation, which indicates the neurospecificity of this model. Conclusions: The primary patient-derived glioblastoma culture 022 may serve as a more relevant model of glioblastoma compared to the U87MG cell line-based model.
Список научных проектов, где отмечена публикация
- Identification of genes as potential targets for therapy of neurogenic tumors (January 6, 2024 December 31, 2026). . Grant, RSF.
- Complex effects on tumors and tumor microenvironment using multimodal hybrid protein constructs and approaches to the development of multitarget protein therapeutics (January 6, 2024 December 31, 2026). . Grant, RSF.


: